UNLABELLED: Heparan sulfate proteoglycans (HSPGs) act as coreceptors or storage sites for growth factors and cytokines such as fibroblast growth factor and Wnts. Glypican 3 (GPC3) is the most highly expressed HSPG in hepatocellular carcinoma (HCC). Sulfatase 2 (SULF2), an enzyme with 6-O-desulfatase activity on HSPGs, is up-regulated in 60% of primary HCCs and is associated with a worse prognosis. We have previously shown that the oncogenic effect of SULF2 in HCC may be mediated in part through up-regulation of GPC3. Here we demonstrate that GPC3 stimulates the Wnt/β-catenin pathway and mediates the oncogenic function of SULF2 in HCC. Wnt signaling in vitro and in vivo was assessed in SULF2-negative Hep3B HCC cells transfected with SULF2 and in SULF2-expressing Huh7 cells transfected with short hairpin RNA targeting SULF2. The interaction between GPC3, SULF2, and Wnt3a was assessed by coimmunoprecipitation and flow cytometry. β-catenin-dependent transcriptional activity was assessed with the TOPFLASH (T cell factor reporter plasmid) luciferase assay. In HCC cells, SULF2 increased cell surface GPC3 and Wnt3a expression, stabilized β-catenin, and activated T cell factor transcription factor activity and expression of the Wnt/β-catenin target gene cyclin D1. Opposite effects were observed in SULF2-knockdown models. In vivo, nude mouse xenografts established from SULF2-transfected Hep3B cells showed enhanced GPC3, Wnt3a, and β-catenin levels. CONCLUSION: Together, these findings identify a novel mechanism mediating the oncogenic function of SULF2 in HCC that includes GPC3-mediated activation of Wnt signaling via the Wnt3a/glycogen synthase kinase 3 beta axis.
UNLABELLED: Heparan sulfate proteoglycans (HSPGs) act as coreceptors or storage sites for growth factors and cytokines such as fibroblast growth factor and Wnts. Glypican 3 (GPC3) is the most highly expressed HSPG in hepatocellular carcinoma (HCC). Sulfatase 2 (SULF2), an enzyme with 6-O-desulfatase activity on HSPGs, is up-regulated in 60% of primary HCCs and is associated with a worse prognosis. We have previously shown that the oncogenic effect of SULF2 in HCC may be mediated in part through up-regulation of GPC3. Here we demonstrate that GPC3 stimulates the Wnt/β-catenin pathway and mediates the oncogenic function of SULF2 in HCC. Wnt signaling in vitro and in vivo was assessed in SULF2-negative Hep3B HCC cells transfected with SULF2 and in SULF2-expressing Huh7 cells transfected with short hairpin RNA targeting SULF2. The interaction between GPC3, SULF2, and Wnt3a was assessed by coimmunoprecipitation and flow cytometry. β-catenin-dependent transcriptional activity was assessed with the TOPFLASH (T cell factor reporter plasmid) luciferase assay. In HCC cells, SULF2 increased cell surface GPC3 and Wnt3a expression, stabilized β-catenin, and activated T cell factor transcription factor activity and expression of the Wnt/β-catenin target gene cyclin D1. Opposite effects were observed in SULF2-knockdown models. In vivo, nude mouse xenografts established from SULF2-transfected Hep3B cells showed enhanced GPC3, Wnt3a, and β-catenin levels. CONCLUSION: Together, these findings identify a novel mechanism mediating the oncogenic function of SULF2 in HCC that includes GPC3-mediated activation of Wnt signaling via the Wnt3a/glycogen synthase kinase 3 beta axis.
Authors: Z W Zhu; H Friess; L Wang; M Abou-Shady; A Zimmermann; A D Lander; M Korc; J Kleeff; M W Büchler Journal: Gut Date: 2001-04 Impact factor: 23.059
Authors: Jin-Ping Lai; Chunrong Yu; Catherine D Moser; Ileana Aderca; Tao Han; Thomas D Garvey; Linda M Murphy; Megan M Garrity-Park; Viji Shridhar; Alex A Adjei; Lewis R Roberts Journal: Gastroenterology Date: 2006-06 Impact factor: 22.682
Authors: Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Tao Han; Catherine D Moser; Kenard K Jackson; Ruben Bonilla Guerrero; Ileana Aderca; Hajime Isomoto; Megan M Garrity-Park; Hongzhi Zou; Abdirashid M Shire; David M Nagorney; Schuyler O Sanderson; Alex A Adjei; Ju-Seog Lee; Snorri S Thorgeirsson; Lewis R Roberts Journal: Hepatology Date: 2008-04 Impact factor: 17.425
Authors: H Lemjabbar-Alaoui; A van Zante; M S Singer; Q Xue; Y-Q Wang; D Tsay; B He; D M Jablons; S D Rosen Journal: Oncogene Date: 2009-10-26 Impact factor: 9.867
Authors: A Bengochea; M M de Souza; L Lefrançois; E Le Roux; O Galy; I Chemin; M Kim; J R Wands; C Trepo; P Hainaut; J-Y Scoazec; L Vitvitski; P Merle Journal: Br J Cancer Date: 2008-06-24 Impact factor: 7.640
Authors: Jin-Ping Lai; Dalbir S Sandhu; Chunrong Yu; Catherine D Moser; Chunling Hu; Abdirashid M Shire; Ileana Aderca; Linda M Murphy; Alex A Adjei; Schuyler Sanderson; Lewis R Roberts Journal: Liver Int Date: 2010-09-08 Impact factor: 5.828
Authors: Ryan M Carr; Paola A Romecin Duran; Ezequiel J Tolosa; Chenchao Ma; Abdul M Oseini; Catherine D Moser; Bubu A Banini; Jianbo Huang; Faizal Asumda; Renumathy Dhanasekaran; Rondell P Graham; Merih D Toruner; Stephanie L Safgren; Luciana L Almada; Shaoqing Wang; Mrinal M Patnaik; Lewis R Roberts; Martin E Fernandez-Zapico Journal: J Biol Chem Date: 2020-01-27 Impact factor: 5.157
Authors: Ashwani Khurana; Han W Tun; Laura Marlow; John A Copland; Keith Dredge; Viji Shridhar Journal: Mol Carcinog Date: 2011-07-07 Impact factor: 4.784